Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carboxy-PTIO (2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide) is a cell-impermeable small molecule that functions as a potent and specific scavenger of nitric oxide (NO). It reacts stoichiometrically with nitric oxide radicals to generate nitrogen dioxide (NO2) and the corresponding imino nitroxide derivative (PTI). Unlike many other nitric oxide synthase (NOS) inhibitors that prevent the production of NO, carboxy-PTIO directly neutralizes existing NO, making it an essential biochemical tool for differentiating the physiological and pathological effects of NO from other reactive oxygen or nitrogen species. While primarily used as a research reagent, it has been investigated in preclinical models for potential therapeutic applications in conditions involving excessive NO production, such as endotoxic shock, systemic hypotension, and acute renal failure associated with septic shock. It is available in both a free acid form and a potassium salt form, the latter providing improved aqueous solubility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxy-PTIO.